Summary
Serum high density lipoprotein (HDL) subfractions HDL2 and HDL3, apolipoproteins, and plasma antipyrine clearance (AP-CL) rate, an index of liver microsomal enzyme activity, were determined in 21 healthy subjects. High HDL cholesterol and HDL2 cholesterol concentrations and HDL cholesterol/cholesterol and HDL2/HDL3 cholesterol ratios were associated with high AP-CL. Phenobarbital enhanced antipyrine elimination and increased the apolipoprotein A-I/A-II ratio. Subjects who had high AP-CL had a more antiatherogenic HDL subfraction and apolipoprotein profile than those with low AP-CL.
This is a preview of subscription content, log in via an institution to check access.
References
Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High-density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 62: 707–714
Miller NE (1987) Association of high density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 113: 589–597
Naito HK (1985) The association of serum lipids, lipoproteins and apolipoproteins with coronary artery disease assessed by coronary arteriography. Ann NY Acad Sci 454: 230–238
DeBacker G, Rosseneau M, Deslypere J (1982) Discriminative value of lipids and apoproteins in coronary heart disease. Atherosclerosis 42: 197–203
Lipid Research Clinics Program (1984) The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365–374
Levy RI, Brensike JF, Epstein SE, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW, Moriaty DJ, Detre KM (1984) The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary disease: results of the NHLBI type II coronary intervention study. Circulation 69: 325–337
Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjäblom T, Nikkilä EA (1987) Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237–1245
Luoma PV (1988) Microsomal enzyme induction, lipoproteins and atherosclerosis. Pharmacol Toxicol 62: 243–249
Luoma PV, Sotaniemi EA, Pelkonen RO, Savolainen MJ, Ehnholm C (1982) Induction and lipoproteins. Lancet 1: 625
Luoma PV, Sotaniemi EA, Arranto AJ (1983) Serum LDL cholesterol and the LDL/HDL cholesterol ratio and liver microsomal enzyme induction evaluated by antipyrine kinetics. Scand J Clin Lab Invest 43: 671–675
Nadir HH, Al-Dabbagh SG, Idle JR (1982) Elevated serum cholesterol in drug-oxidation deficient rats. Biochem Pharmacol 31: 1665–1668
Luoma PV, Korpela H, Sotaniemi EA, Kumpulainen J (1985) Serum selenium, glutathione peroxidase, lipids and human liver microsomal activity. Biol Trace Elem Res 8: 113–121
Lehtonen A, Himanen P, Saraste M, Niittymäki K, Marniemi J (1986) Double-blind comparison of the effects of long-term treatment with doxazosin or athenol on serum lipoproteins. Br J Clin Pharmacol 21: 77S-81S
Myasnikov AL (1958) Influence of some factors on development of experimental cholesterol atherosclerosis. Circulation 17: 99–113
Salvador RA, Atkins C, Haber S, Kozma C, Conney AH (1970) Effect of phenobarbital and chlorcyclizine on the development of atheromatosis in the cholesterol-fed rabbit. Biochem Pharmacol 19: 1875–1881
Muuronen A, Kaste M, Nikkilä EA, Tolppanen E-M (1985) Mortality from ischaemic heart disease among patients using anticonvulsive drugs; a case-control study. Br Med J 291: 1481–1483
Conney AH (1967) Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 19: 317–366
Chao Y-S, Pickett CB, Yamin T-T, Guo LSS, Alberts AW, Kroon PA (1985) Phenobarbital induces rat liver apolipoprotein A-I mRNA. Mol Pharmacol 27: 394–398
Luoma PV, Sotaniemi EA, Savolainen MJ, Pelkonen RO, Ehnholm C (1986) Increase in apolipoprotein A-I/A-II ratio in phenytoin users — Positive relation to liver protein and cytochrome P-450. Abstr. Acta Pharmacol Toxicol [Suppl V]: 165
Parke DV (1981) The endoplasmic reticulum: its role in physiological functions and pathological situations. In: Jenner P, Testa B (eds) Concepts in drug metabolism, Part B. Dekker, New York
Miettinen TA (1975) Bile acid metabolism. In: Kritchevsky D (ed) Hypolipidemic agents. Springer, Berlin Heidelberg New York
Miller NE, Nestel PJ (1973) Altered bile acid metabolism during treatment with phenobarbitone. Clin Sci Mol Med 45: 257–262
Miettinen TA, Gylling H (1988) Mortality and cholesterol metabolism in familial hypercholesterolemia. Arteriosclerosis 8: 163–167
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Luoma, P.V., Rautio, A., Steng»rd, J. et al. High-density lipoprotein subfractions, apolipoproteins and antipyrine clearance in normal subjects. Eur J Clin Pharmacol 38, 625–627 (1990). https://doi.org/10.1007/BF00278594
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00278594